Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant SurgeDavid T. Huang, Christopher Seymour, David A. Nace et al.|JAMA Network Open|2022Cited by 54
Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19Erin K McCreary, Kevin E. Kip, J Ryan Bariola et al.|JAMA Network Open|2022Cited by 36
The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trialErin K McCreary, David T. Huang, J Ryan Bariola et al.|Contemporary Clinical Trials|2022Cited by 26
The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomizationDavid T. Huang, Derek C. Angus, Erin K McCreary et al.|Trials|2021Cited by 25
Effectiveness of casirivimab and imdevimab, and sotrovimab during Delta variant surge: a prospective cohort study and comparative effectiveness randomized trialDavid T. Huang, Christopher Seymour, Erin K McCreary et al.|medRxiv|2021Cited by 15